LLY - Lilly woes provide buying opportunity Danaher a buy with likely earnings beat and more in today's analyst action

Lilly's recent setback provide buying opportunityAlthough Eli Lilly's (LLY) share price has been hit since reporting after the bell on Tuesday that the FDA is extending the review of an sNDA for Olumiant (baricitinib) in atopic dermatitis, Cantor Fitzgerald indicates this has provided a buying opportunity."You're Gonna Miss This Opportunity When It's Gone, Time To Take Another Look With The Pullback" reads the headline of a note today.Cantor has an overweight rating on shares.Lilly suffered another woe today, reporting that baricitinib failed to meet its primary endpoint in a COVID-19 trial.Danaher new positive catalyst watch at CitiCiti analyst Patrick Donnelly expects Danaher (DHR) to beat Q1 21 bioprocessing expectations, and as a result, is initiating the stock as a positive catalyst watch.He says a potential Q1 beat and guidance raise later this month could move shares higher.Donnelly adds that molecular point-of-care testing remains the most durable testing method for COVID-19, and

For further details see:

Lilly woes provide buying opportunity, Danaher a buy with likely earnings beat, and more in today's analyst action